Clinical trial of budesonide formoterol,ipratropium bromide combined with NIPPV in the treatment of elderly patients with COPD complicated with type Ⅱ respiratory failure
10.13699/j.cnki.1001-6821.2023.24.002
- VernacularTitle:布地奈德福莫特罗、异丙托溴铵联合NIPPV治疗COPD合并Ⅱ型呼吸衰竭老年患者的临床研究
- Author:
Yu ZHANG
1
;
Jiang REN
;
Zhen-Xing YAN
;
He-Feng TANG
Author Information
1. 绍兴市人民医院急诊科,浙江绍兴 312000
- Keywords:
budesonide;
ipratropium bromide;
chronic obstructive pulmonary disease;
type Ⅱ respiratory failure;
noninvasive positive pressure ventilation;
elderly
- From:
The Chinese Journal of Clinical Pharmacology
2023;39(24):3552-3555
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze and study the actual therapeutic effect of the combined treatment of budesonide-formoterol and ipratropium bromide with non-invasive positive pressure ventilation(NIPPV)in elderly patients with chronic obstructive pulmonary disease(COPD)and type Ⅱ respiratory failure.Methods Patients diagnosed clinically with COPD and type Ⅱ respiratory failure were selected for the study.The control group received NIPPV-style oxygen therapy for 3-4 hours each time,tid,for a total of 28 days,while the treatment group received budesonide-formoterol inhalation powder 1 inhalation and ipratropium bromide solution 2 mL aerosol inhalation on the basis of control group,twice a day for three consecutive days,for a total of four treatment cycles,with a cycle interval of 4 days and a total treatment duration of 28 days.Changes in arterial carbon dioxide partial pressure(PaCO2),the ratio of forced expiratory volume in one second to forced vital capacity(FEV1/FVC),6-minute walk test distance,BODE index,and other indicators were observed before and after treatment in the two groups.Results A total of 115 patients were included in the study,including 58 in the control group and 57 in the treatment group.After treatment,the FEV1/FVC in the treatment group and the control group were(65.12±5.11)％and(60.12±1.43)％,respectively;PaCO2 were(36.99±3.28)and(40.05±1.46)mmHg,respectively;6-minute walk test distances were(459.15±17.25)and(400.15±25.16)m,respectively;BODE index were 3.00±0.42 and 3.81±0.28,respectively.The overall survival rates in the two groups after 1 year were(88.14±12.16)％and(71.14±11.14)％,respectively,and the rates of improvement in lung function were 73.68％(42 cases/57 cases)and 58.62％(34 cases/58 cases),respectively.The differences in these indicators between the two groups were statistically significant(all P＜0.05).The incidence of drug adverse reactions in the treatment group and the control group were 21.05％(12 cases/57 cases)and 18.97％(11 cases/58 cases),respectively,without significant difference(P＞0.05).Conclusion The combined treatment of budesonide-formoterol and ipratropium bromide with NIPPV can significantly improve the exercise tolerance of patients with COPD and type Ⅱ respiratory failure.It can also significantly reduce BODE index and delay the occurrence of all-cause mortality events within 1 year.
